ACE2 and diabetic kidney disease: ACE2 provided significant renal protection in patients with diabetes, while ACE2 deficiency aggravated diabetic kidney injury, rhACE2 has therapeutic effects in experimental Alport syndrome and diabetic nephropathy.[44,45] The results of Marfella et al[46] showed that high glucose environment was more conducive to the formation of glycosylated ACE2, and the expression of glycosylated ACE2 in cardiomyocytes was strongly correlated with blood glucose control.